Photo of David J. Einstein, MD

David J. Einstein, MD

Beth Israel Deaconess Medical Center

Beth Israel Deaconess Medical Center

Photo of David J. Einstein, MD

Beth Israel Deaconess Medical Center

Visualize Collaborations
Learn how these members are similar
Similar Members

DF/HCC members that share similar concepts* with David J. Einstein, MD but have yet to coauthor a publication with this researcher.

* Concepts are MeSH terms, automatically derived from member publications

Similar Members

David J. Einstein, MD

Beth Israel Deaconess Medical Center

EDUCATIONAL TITLES

  • Assistant Professor, Medicine, Harvard Medical School
  • Attending Physician, Medicine, Beth Israel Deaconess Medical Center

DF/HCC PROGRAM AFFILIATION

Research Abstract

I am an academic medical oncologist specializing in genitourinary cancers. I care for patients with prostate, bladder, and testicular cancer.

I am interested in clinical trial development and serve as overall PI and site PI of several DFHCC clinical trials that investigate immuno-oncology and targeted agents for GU cancers. I am a member of a team funded by a Challenge Award from the Prostate Cancer Foundation that is exploring immuno-oncology in prostate cancer. I am also interested in biomarkers for differentiating indolent from potentially aggressive "low-risk" prostate cancer, a project supported by a grant from the Department of Defense. I lead the GU Rapid Autopsy project at DFHCC, which offers patients the opportunity to leave a scientific legacy and offers scientists the opportunity to study tumor hetereogeneity and mechanisms of resistance to treatment.

I am also interested in improving physician communication about difficult topics ranging from clinical trial enrollment to advance-care planning. I have published studies of the integration of palliative care into oncologic care and end-of-life discussions between residents and cancer patients, and I have been an invited speaker at the Boston Prostate Cancer Support Group.

Publications from Harvard Catalyst Profiles

Powered by Harvard Catalyst
  • Sentana-Lledo D, Sartor O, Balk SP, Einstein DJ. Immune mechanisms behind prostate cancer in men of African ancestry: A review. Prostate 2022; 82:883-893. PubMed
  • Atkins MB, Jegede OA, Haas NB, McDermott DF, Bilen MA, Stein M, Sosman JA, Alter R, Plimack ER, Ornstein M, Hurwitz M, Peace DJ, Signoretti S, Denize T, Cimadamore A, Wu CJ, Braun D, Einstein D, Catalano PJ, Hammers H. Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A). J Clin Oncol 2022. PubMed
  • Ma F, Arai S, Wang K, Calagua C, Yuan AR, Poluben L, Gu Z, Russo JW, Einstein DJ, Ye H, He MX, Liu Y, Van Allen E, Sowalsky AG, Bhasin MK, Yuan X, Balk SP. Autocrine Canonical Wnt Signaling Primes Noncanonical Signaling through ROR1 in Metastatic Castration-Resistant Prostate Cancer. Cancer Res 2022; 82:1518-1533. PubMed
  • Calagua C, Ficial M, Jansen CS, Hirz T, Del Balzo L, Wilkinson S, Lake R, Ku AT, Voznesensky O, Sykes DB, Saylor PJ, Ye H, Signoretti S, Kissick H, Sowalsky AG, Balk SP, Einstein DJ. A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes. Clin Cancer Res 2021. PubMed
  • Santopietro AL, Einstein D, Bellmunt J. Advances in the management of urothelial carcinoma: is immunotherapy the answer? Expert Opin Pharmacother 2021. PubMed
  • Morel KL, Sheahan AV, Burkhart DL, Baca SC, Boufaied N, Liu Y, Qiu X, Cañadas I, Roehle K, Heckler M, Calagua C, Ye H, Pantelidou C, Galbo P, Panja S, Mitrofanova A, Wilkinson S, Whitlock NC, Trostel SY, Hamid AA, Kibel AS, Barbie DA, Choudhury AD, Pomerantz MM, Sweeney CJ, Long HW, Einstein DJ, Shapiro GI, Dougan SK, Sowalsky AG, He HH, Freedman ML, Balk SP, Loda M, Labbé DP, Olson BM, Ellis L. EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer. 2021; 2:444-456. PubMed
  • McKay RR, Xie W, Ye H, Fennessy FM, Zhang Z, Lis R, Calagua C, Rathkopf D, Laudone VP, Bubley GJ, Einstein DJ, Chang PK, Wagner AA, Parsons JK, Preston MA, Kilbridge K, Chang SL, Choudhury AD, Pomerantz MM, Trinh QD, Kibel AS, Taplin ME. Results of a Randomized Phase II Trial of Intense Androgen Deprivation Therapy prior to Radical Prostatectomy in Men with High-Risk Localized Prostate Cancer. J Urol 2021. PubMed
  • Patell R, Einstein D, Miller E, Dodge L, Halleck J, Buss M. Patient Perceptions of Treatment Benefit and Toxicity in Advanced Cancer: A Prospective Cross-Sectional Study. JCO Oncol Pract 2021; 17:e119-e129. PubMed
  • Halbert B, Einstein DJ. Hot or Not: Tumor Mutational Burden (TMB) as a Biomarker of Immunotherapy Response in Genitourinary Cancers. Urology 2021; 147:119-126. PubMed
  • Awasthi S, Berglund A, Abraham-Miranda J, Rounbehler RJ, Kensler K, Serna A, Vidal A, You S, Freeman MR, Davicioni E, Liu Y, Karnes RJ, Klein EA, Den RB, Trock BJ, Campbell JD, Einstein DJ, Gupta R, Balk S, Lal P, Park JY, Cleveland JL, Rebbeck TR, Freedland SJ, Yamoah K. Comparative Genomics Reveals Distinct Immune-oncologic Pathways in African American Men with Prostate Cancer. Clin Cancer Res 2021; 27:320-329. PubMed
  • Cole SM, Sarangi S, Einstein D, McMasters M, Alterman R, Bruce J, Hertan L, Shih HA, Wong ET. Parkinsonism reversed from treatment of pineal non-germinomatous germ cell tumor. Surg Neurol Int 2021; 12:237. PubMed
  • Einstein DJ, Arai S, Calagua C, Xie F, Voznesensky O, Capaldo BJ, Luffman C, Hecht JL, Balk SP, Sowalsky AG, Russo JW. Metastatic Castration-Resistant Prostate Cancer Remains Dependent on Oncogenic Drivers Found in Primary Tumors. JCO Precis Oncol 2021. PubMed
  • Bilusic M, Einstein DJ, Karzai FH, Dahut WL, Gulley JL, Aragon-Ching JB, Madan RA. The Potential Role for Immunotherapy in Biochemically Recurrent Prostate Cancer. Urol Clin North Am 2020; 47:457-467. PubMed
  • Garnick MB, Einstein DJ. EDITORIAL COMMENT. Urology 2019; 131:182-183. PubMed
  • Einstein DJ, Arai S, Balk SP. Targeting the androgen receptor and overcoming resistance in prostate cancer. Curr Opin Oncol 2019. PubMed
  • Einstein DJ, Patil D, Chipman J, Regan MM, Davis K, Crociani CM, Wagner AA, Sanda M, Chang P. Expanded Prostate Cancer Index Composite-26 (EPIC-26) Online: Validation of an Internet-Based Instrument for Assessment of Health-Related Quality of Life after Treatment for Localized Prostate Cancer. Urology 2019. PubMed
  • Einstein DJ, Sonpavde G. Treatment Approaches for Cisplatin-Ineligible Patients with Invasive Bladder Cancer. Curr Treat Options Oncol 2019; 20:12. PubMed
  • Hennigan ST, Trostel SY, Terrigino NT, Voznesensky OS, Schaefer RJ, Whitlock NC, Wilkinson S, Carrabba NV, Atway R, Shema S, Lake R, Sweet AR, Einstein DJ, Karzai F, Gulley JL, Chang P, Bubley GJ, Balk SP, Ye H, Sowalsky AG. Low Abundance of Circulating Tumor DNA in Localized Prostate Cancer. JCO Precis Oncol 2019. PubMed
  • Einstein DJ. Compassion and Compassionate Use. J Clin Oncol 2018; 36:2969-2971. PubMed
  • Russo JW, Liu X, Ye H, Calagua C, Chen S, Voznesensky O, Condulis J, Ma F, Taplin ME, Einstein DJ, Balk SP, Chen S. Phosphorylation of androgen receptor serine 81 is associated with its reactivation in castration-resistant prostate cancer. Cancer Lett 2018; 438:97-104. PubMed
  • Einstein DJ, McDermott DF. Combined blockade of vascular endothelial growth factor and programmed death 1 pathways in advanced kidney cancer. Clin Adv Hematol Oncol 2017; 15:478-488. PubMed
  • Einstein DJ, DeSanto-Madeya S, Gregas M, Lynch J, McDermott DF, Buss MK. Improving End-of-Life Care: Palliative Care Embedded in an Oncology Clinic Specializing in Targeted and Immune-Based Therapies. J Oncol Pract 2017. PubMed
  • Mathew P, Einstein DJ, Ladin K. Against "Healthy Paternalism" at the End of Life-Reply. JAMA Oncol 2016; 2:833. PubMed
  • Einstein DJ, Ladin K, Mathew P. The Ethical Imperative of Healthy Paternalism in Advance Directive Discussions at the End of Life. JAMA Oncol 2016; 2:429-30. PubMed
  • Einstein DJ, Trowbridge RL, Rencic J. A Problematic Palsy: An Exercise in Clinical Reasoning. J Gen Intern Med 2015; 30:1029-33. PubMed
  • Einstein DJ, Einstein KL, Mathew P. Dying for Advice: Code Status Discussions between Resident Physicians and Patients with Advanced Cancer--A National Survey. J Palliat Med 2015; 18:535-41. PubMed
Hide
Visualize Collaborations
Learn how these members are similar
Similar Members

DF/HCC members that share similar concepts* with David J. Einstein, MD but have yet to coauthor a publication with this researcher.

* Concepts are MeSH terms, automatically derived from member publications

Similar Members